Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $236.8 million.

  • Kiniksa Pharmaceuticals International's Non-Current Assets fell 294.84% to $236.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $969.8 million, marking a year-over-year decrease of 149.27%. This contributed to the annual value of $248.8 million for FY2024, which is 50.83% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Non-Current Assets is $236.8 million, which was down 294.84% from $240.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Non-Current Assets' 5-year high stood at $250.0 million during Q4 2023, with a 5-year trough of $30.6 million in Q2 2022.
  • Its 5-year average for Non-Current Assets is $172.1 million, with a median of $227.0 million in 2023.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Non-Current Assets tumbled by 1093.09% in 2022, and later soared by 67776.62% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Non-Current Assets stood at $36.4 million in 2021, then skyrocketed by 495.84% to $216.6 million in 2022, then rose by 15.43% to $250.0 million in 2023, then fell by 0.51% to $248.8 million in 2024, then fell by 4.8% to $236.8 million in 2025.
  • Its Non-Current Assets stands at $236.8 million for Q3 2025, versus $240.8 million for Q2 2025 and $243.4 million for Q1 2025.